Madhu Kumar
Stock Analyst at Goldman Sachs
(2.88)
# 1,797
Out of 5,111 analysts
145
Total ratings
56.44%
Success rate
20.33%
Average return
Main Sectors:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $162 → $185 | $167.50 | +10.45% | 8 | Aug 29, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $13.00 | -53.85% | 8 | Jan 26, 2024 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $10.23 | +66.18% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $1.49 | +168.46% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $244.65 | -36.64% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $63.35 | -16.34% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $9.43 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $70.09 | +4.15% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $25.23 | +458.86% | 9 | Apr 14, 2023 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $39 → $34 | $20.37 | +66.91% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $2.20 | +172.73% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $7.46 | +87.67% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $21 | $10.81 | +94.35% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $23.62 | -78.83% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $2.53 | +216.21% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $12.58 | +607.47% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $580 → $120 | $9.80 | +1,125.11% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $10 | $0.12 | +8,425.15% | 1 | Aug 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $9.02 | +842.35% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $4.68 | +733.33% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $19.51 | +192.16% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.71 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $0.93 | +96,166.98% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $6.69 | +198.95% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $0.39 | +25,580.53% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $46.87 | -25.33% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $15.99 | +150.16% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $36.10 | +1,296.12% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $397.55 | -42.15% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $1,125 | $14.09 | +7,884.39% | 2 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $1.05 | +3,709.52% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $31.35 | -31.42% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $56.68 | -58.54% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Aug 29, 2025
Maintains: Buy
Price Target: $162 → $185
Current: $167.50
Upside: +10.45%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $13.00
Upside: -53.85%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $10.23
Upside: +66.18%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $1.49
Upside: +168.46%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $244.65
Upside: -36.64%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $63.35
Upside: -16.34%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $9.43
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $70.09
Upside: +4.15%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $25.23
Upside: +458.86%
Syndax Pharmaceuticals
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $20.37
Upside: +66.91%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $2.20
Upside: +172.73%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $7.46
Upside: +87.67%
Nov 4, 2022
Maintains: Buy
Price Target: $24 → $21
Current: $10.81
Upside: +94.35%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $23.62
Upside: -78.83%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $2.53
Upside: +216.21%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $12.58
Upside: +607.47%
Jan 19, 2022
Downgrades: Neutral
Price Target: $580 → $120
Current: $9.80
Upside: +1,125.11%
Aug 27, 2021
Downgrades: Sell
Price Target: $10
Current: $0.12
Upside: +8,425.15%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $9.02
Upside: +842.35%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $4.68
Upside: +733.33%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $19.51
Upside: +192.16%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.71
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $0.93
Upside: +96,166.98%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $6.69
Upside: +198.95%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $0.39
Upside: +25,580.53%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $46.87
Upside: -25.33%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $15.99
Upside: +150.16%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $36.10
Upside: +1,296.12%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $397.55
Upside: -42.15%
Feb 9, 2018
Maintains: Buy
Price Target: $150 → $1,125
Current: $14.09
Upside: +7,884.39%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $1.05
Upside: +3,709.52%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $31.35
Upside: -31.42%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $56.68
Upside: -58.54%